Viking Therapeutics

Viking Therapeutics

Yahoo Finance • 3 days ago

Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics?

Demand for GLP-1 drugs is soaring. Thanks to recent breakthroughs, medicines in this category are expanding their addressable markets and treating conditions such as obstructive sleep apnea (OSA), metabolic dysfunction-associated steatohep... Full story

Yahoo Finance • 13 days ago

Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline ...

This article first appeared on GuruFocus. Net Loss (Q2 2026): $128.1 million, or $1.10 per share, compared to a net loss of $65.6 million, or $0.58 per share, in Q2 2025. Net Loss (Six Months Ended June 30, 2026): $286.5 million, or $2.47... Full story

Yahoo Finance • 13 days ago

3 Biotech Stocks With Massive Upside to Buy Before August Starts

Quick Read REGN sits 15% below its year-start price despite strong earnings, while MRNA has surged 177% into an August 5 FDA flu vaccine ruling. VKTX carries 175% analyst upside potential but remains pre-revenue, making its dual GLP-1/GIP... Full story

Yahoo Finance • 19 days ago

Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Viking Therapeutics stock has delivered a very large 5 year return, yet its current valuation checks lean expensive, settin... Full story

Yahoo Finance • 19 days ago

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

Experienced Executive Brings Over Two Decades of Leadership Across Healthcare, Digital Health and Commercialization SAN DIEGO,, July 23, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceu... Full story

Yahoo Finance • 21 days ago

A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

Issued on behalf of Avaí Bio, Inc. (OTCQB: AVAI) LAS VEGAS, July 21, 2026 /PRNewswire/ -- (American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been t... Full story

Yahoo Finance • 24 days ago

Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes."

Following an excellent run in June, when the stock rose by more than 19%, Viking Therapeutics (NASDAQ: VKTX) stock recently dipped, potentially creating a buying opportunity for an exciting growth stock with huge potential in the weight-lo... Full story

Yahoo Finance • 25 days ago

The weight-loss drugs boom is creating both winners and wipeouts: One Big Investment Idea

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures. A single clinical result can send a stock soaring, wipe out years of gains, or threaten the company itself. Drug develo... Full story

Yahoo Finance • 26 days ago

Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm

NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Viking Therapeutics, Inc. (NASDAQ: VKTX) breached their fiduciary duties to shareh... Full story

Yahoo Finance • 27 days ago

As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22

Issued on behalf of MindWalk Holdings Corp. MindWalk Holdings Corp. (NASDAQ: HYFT) heads into its fourth-quarter and full-year results with fresh index inclusion, an expanded patent estate, and AI-designed programs aimed at two of medicin... Full story

Yahoo Finance • 28 days ago

Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates

Dublin, July 15, 2026 (GLOBE NEWSWIRE) -- The "Oral Obesity Therapies Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Oral Obesity Therapies Market Global Report 2026 provides strategists, marketers, invest... Full story

Yahoo Finance • last month

Is This Biotech Stock a Buy After Its Massive Rally?

Viking Therapeutics (NASDAQ: VKTX) may be one of biotech's most tempting buyout targets, thanks to its weight loss drug pipeline and massive obesity market opportunity. But the stock also carries serious risk, especially as a better-funded... Full story

Yahoo Finance • last month

Novo Nordisk (NYSE:NVO) Updates Wegovy Label In Singapore With STEP UP Data

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novo Nordisk (NYSE:NVO) has updated the Wegovy label in Singapore to include new STEP UP trial data for adults with ob... Full story

Yahoo Finance • last month

3 High Growth GLP-1 Biotech Winners to Buy in July

Quick Read LLY beat Q1 EPS estimates by 26% and launched Foundayo, while beaten-down NVO trades near 10x earnings and 45% below its 52-week high. Viking's pre-revenue VKTX carries binary Phase 3 risk, but VK2735 showed 12% mean body weigh... Full story

Yahoo Finance • last month

Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the ob... Full story

Yahoo Finance • last month

Viking Therapeutics (VKTX) Could Be 120% Undervalued On Obesity Pipeline Progress

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Viking Therapeutics (VKTX) recently started a Phase 1 single ascending dose clinical trial of VK30... Full story

Yahoo Finance • last month

Eli Lilly's Market Cap Balloons Again On This IPO's Setback

Eli Lilly shares hit a record high Tuesday after IPO stock Kailera Therapeutics posted lackluster test results for its weight-loss pill. Continue Reading... Full story

Yahoo Finance • last month

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pip... Full story

Yahoo Finance • last month

CRISPR Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Key Points CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic diso... Full story

Yahoo Finance • last month

Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?

The short, but glib, answer to the headline question posed for Viking Therapeutics (NASDAQ: VKTX) investors is "no," because the likelihood is that the $4.6 billion market cap company will be bought up by a larger pharmaceutical company if... Full story